Veraxa Biotech received scientific advice from Germany’s Paul-Ehrlich-Institute (PEI) regarding the biology and nonclinical development plan for its BiTAC-TCE T-cell engager program. The feedback centers on Veraxa’s most advanced development program using its proprietary BiTAC-TCE platform, a mechanism intended to engage tumor-associated cytotoxicity through targeted T-cell engagement. The company said PEI’s input addresses the underlying biology and the proposed nonclinical package. For early-to-mid stage biotech programs, such advice can compress uncertainty around study design, dosing rationale, and regulatory expectations before formal filings. Veraxa’s next steps will focus on translating PEI’s guidance into an execution roadmap for the nonclinical work ahead of potential clinical entry or further development.